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Background—Current heart failure (HF) risk prediction models do not consider how individual 
patient assessments occur in incremental steps; furthermore, each additional diagnostic evaluation 
may add cost, complexity, and potential morbidity.
Methods and Results—Using a cohort of well-treated ambulatory HF patients with reduced 
ejection fraction (HFrEF) with complete clinical, laboratory, health-related quality of life, 
imaging, and exercise testing data, we estimated incremental prognostic information provided by 
five assessment categories, performing an additional analysis on those with available N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) levels. We compared the incremental value of each 
additional assessment (quality of life screen, laboratory testing, echocardiography, exercise 
testing) to baseline clinical assessment for predicting clinical outcomes (all-cause mortality, all-
cause mortality/hospitalization, cardiovascular death/HF hospitalizations), gauging incremental 
improvements in prognostic ability with more information using area under the curve and 
reclassification improvement (Net Reclassification Index; NRI), with and without NT-proBNP 
availability. Of 2331 participants, 1631 patients had complete clinical data; of these, 1023 had 
baseline NT-proBNP. For prediction of all-cause mortality, models with incremental assessments 
sans NT-proBNP showed improvements in C-indices (0.72[clinical model alone]–0.77[complete 
model]). Compared to baseline clinical assessment alone, NRI improved from 0.035 (w/laboratory 
data) to 0.085 (complete model). These improvements were significantly attenuated for models in 
the subset with measured NT-proBNP data (c-indices: 0.80[w/laboratory data]–0.81[full model]); 
NRI improvements were similarly marginal (0.091→0.096); prediction of other clinical outcomes 
had similar findings.
Conclusions—In patients with chronic HFrEF, the marginal benefit of complex prognostic 
evaluations should be weighed against potential patient discomfort and cost escalation.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: 
NCT00047437.
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Approximately 5.1 million people have been diagnosed with heart failure (HF) in the United 
States (U.S.),1 a syndrome that imparts excessive burden on patients and the health care 
system. Within 5 years of diagnosis, HF is responsible for mortality rates approaching 50%, 
and each year, HF is responsible for more than 1 million hospitalizations and more than $30 
billion spent on treatment.2 Furthermore, HF is rapidly becoming the leading cause of death 
and disability in low- and middle-income countries.3
An important rationale for clinical assessments and diagnostic testing in patients with 
chronic HF is to guide therapeutic interventions.4 Quantifying a patient's risk of clinical 
outcomes can provide one way of identifying those who would most benefit from more 
intensive monitoring and treatment.4 Several risk scores and methodologies, ranging from 
simple to complex, have been developed for purposes of HF risk stratification, including 
biomarker testing, imaging modalities, and a variety of multivariable clinical risk scores.1,4 
Nevertheless, in clinical practice, different incremental sets of variables, such as physical 
exam findings and laboratory results, often become available to physicians in a specific 
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sequence (e.g., medical history before serum sodium, before left ventricular ejection fraction 
[LVEF]). Additional testing may be associated with gains in prognostic information, but 
may increase the cost and complexity of care, as well as burden to the patient.
Despite the clinical relevance of this question, the incremental prognostic benefit of 
additional costly and complex clinical assessments remains uncertain. Therefore, we sought 
to measure the incremental prognostic value provided by clinical, quality of life, laboratory, 
echocardiography, and cardiopulmonary exercise testing data in a well-treated cohort of 
ambulatory patients with systolic HF.
Methods
Study Population
Details of the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training 
(HF-ACTION) study have been previously published.5,6 Briefly, HF-ACTION 
(clinicaltrials.gov: NCT00047437) was a randomized clinical trial evaluating the effect of 
exercise training versus usual care on long-term morbidity and mortality in 2331 well-
treated patients with chronic HF due to left ventricular systolic dysfunction (New York 
Heart Association [NYHA] classes II-IV, LVEF <35%). Patients were randomized to either 
usual HF care or a structured, group-based, supervised exercise program. All patients, 
regardless of treatment group, received detailed self-management educational materials that 
included information on medications, fluid management, symptom exacerbation, sodium 
intake, and amount of activity recommended by the American Heart Association (AHA) 
guidelines.7
Assessment of Clinical Variables and Biomarkers
Demographics, socioeconomic status, past medical history, current medications, a physical 
examination, and the most recent laboratory tests were obtained at the baseline clinic visit 
prior to randomization. Participants reported race and ethnicity at the time of study 
enrollment using categories defined by the National Institutes of Health. All patients 
underwent baseline assessments, which included: 1) cardiopulmonary exercise testing; 2) a 
six-minute walk distance (6MWD); 3) transthoracic echocardiography (TTE); 4) quality of 
life measures, ascertained using several validated psychometric instruments measuring 
health-related quality of life, pain, depression, and social support, including the Kansas City 
Cardiomyopathy Questionnaire (KCCQ)8; and 5) levels of N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) in a subset of patients who agreed to participate in the biomarker 
substudy.9,10
Clinical Endpoints
The primary endpoint was a composite of all-cause mortality and all-cause hospitalization 
over a median follow-up of 2.6 years. We examined the following secondary clinical 
endpoints: all-cause death, and all-cause death or HF hospitalization. An independent 
clinical events committee that was blinded to treatment assignment adjudicated all deaths 
and first hospitalizations. Local institutional review boards approved HF-ACTION, and all 
enrolled patients provided written informed consent.
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Among patients used in this analysis, categorical data were summarized as percentages and 
differences in patients with and without NT-proBNP data were compared using chi-square 
tests and Wilcoxon rank-sum tests. A series of Cox proportional hazards regression models 
with a priori variable selection were fit for each clinical endpoint in the full patient 
population and the subgroup with NT-proBNP. The models were as follows (with 
incremental addition of variables [Figure 1]):
1) Baseline clinical assessment: Age, sex, race, education level, marital status, 
employment status, systolic blood pressure, diastolic blood pressure, heart rate, 
body mass index, NYHA class, diabetes, chronic obstructive pulmonary disease, 
smoking status, peripheral vascular disease, atrial fibrillation, hyperlipidemia, 
stroke, depression, any HF hospitalization in the last 6 months, etiology of HF, 
and Canadian Cardiovascular Society angina class;
2) Health-related quality of life: KCCQ;
3) Laboratory assessments: sodium, creatinine, and blood urea nitrogen +/− NT-
proBNP;
4) Echocardiographic assessments: LVEF and mitral regurgitation
5) Walk distance: 6MWD; and
6) Exercise parameters: peak oxygen consumption (VO2) and exercise duration.
We also performed a sensitivity analysis, by considering the 6MWD prior to laboratory 
information, since this assessment is theoretically cheaper and easier to perform in the 
outpatient setting. We estimated the incremental cost of each additional assessment using the 
2012 American Medical Association Current Procedural Terminology manual.11 To account 
for deviations from the linearity assumption in proportional hazards regression, linear 
splines were used for age (>60), 6MWD (<450), peak VO2 (<20), and creatinine (between 
1.0 and 2.3). Hazard ratios are interpreted as the average hazard over the follow-up period to 
address potential deviations from proportional hazards. The time-point for comparison for 
all analyses was 30 months, with censoring of events occurring after 30 months. Each of the 
models was compared to the baseline clinical model that included only variables collected at 
the clinic visit using a 2-category Net Reclassification Index (NRI) split at the endpoint 
incidence rate; 95% confidence intervals for the NRI were created by estimating bootstrap 
standard errors from 50 bootstrap samples. Patients lost to follow-up prior to 30 months 
were considered non-events for NRI calculations. We compared full and reduced models 
using likelihood ratio tests. The same methodology was repeated in the biomarker subset 
with the addition of log-transformed NT-proBNP to the list of laboratory assessments. These 
steps were taken for the three endpoints: all-cause death or hospitalization, all-cause death, 
and cardiovascular death or HF hospitalization. Lastly, we also examined individual 
association or variables with outcomes using the chi-square statistic. We considered p<0.05 
to be statistically significant. All analyses were performed using SAS version 9.2 (SAS 
Institute, Inc., Cary, NC).
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Baseline Characteristics and Increments of Clinical Assessments
Complete clinical data was available on 1631 of 2331 HF-ACTION participants; of these, 
1023 had baseline levels of NT-proBNP. Excluded patients were generally similar to those 
included in the analysis. The Table displays the characteristics of the patient population, as 
well as those with and without baseline NT-proBNP levels. Median age of the study cohort 
was 59 years (25th, 75th percentile: 51, 68); 574 (35%) patients were black, and 1167 (72%) 
were male. The majority of patients were NYHA class II (n=1036, 64%) or class III (n=580, 
36%) at baseline. Median LVEF was 25%, beta-blockers were used in 1545 (95%) patients, 
and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers were used in 
1538 (94%). At baseline, 675 (41%) patients had an implantable cardioverter defibrillator 
and 300 (18%) had a cardiac resynchronization therapy device. The median 6MWD was 368 
meters and the median peak VO2 levels were 14.3 mL/kg/min. Figure 1 depicts the overall 
characteristics of the study population, followed by the variables analyzed during increments 
of clinical assessments. Sets of evaluations were organized according to usual temporality 
during initial assessment of a patient with HF, beginning with a clinical assessment, then 
proceeding with laboratory testing, echocardiography, and exercise testing. Comparison 
between patients with and without available NT-proBNP levels is shown in Supplemental 
Table 1. There were 1031 deaths or hospitalizations in the overall cohort (646 in NT-
proBNP subset), 223 deaths (134 in NT-proBNP subset), and 470 CV death/HF 
hospitalizations (304 in NT-proBNP subset).
Improvements in Prediction of Clinical Outcomes
All-Cause Mortality and All-Cause Hospitalization—Changes in discrimination 
measures with the addition of variables for the composite of all-cause mortality and all-
cause hospitalization are shown in Figure 2a, Figure 3a, and Supplemental Table 2. In the 
overall cohort, baseline clinical information alone yielded a C-index of 0.62, increasing to 
0.65 for the full model. The NRI improved from 0.019 with inclusion of the KCCQ score to 
0.118 for the full model. In the subset of patients with available NT-proBNP levels, 
consideration of clinical, KCCQ, and laboratory information yielded the peak C-index of 
0.67. The NRI increased from 0.112 for the model with baseline clinical information, 
KCCQ, and laboratory data, to 0.169 for the full model.
All-Cause Mortality—Changes in model discrimination with the addition of variables for 
all-cause mortality are shown in Figure 2b, Figure 3b, and Supplemental Table 3. In the 
overall cohort, use of baseline clinical information alone yielded a C-index of 0.72, and with 
the addition of the KCCQ score, laboratory, echocardiography, and exercise parameters, the 
C-index increased to 0.77. The NRI improved from −0.001 after the addition of the KCCQ 
score to 0.085 for the overall set of variables. When analysis was performed in patients with 
available NT-proBNP levels, the C-index increased from 0.73 for baseline clinical 
information alone to 0.80 after consideration of KCCQ score and laboratory parameters. 
Inclusion of additional data increased the C-statistic nominally to 0.81. Similarly, there were 
no appreciable increases in NRI after the addition of laboratory data (0.091→0.096).
Ahmad et al. Page 5













Cardiovascular Death and Heart Failure Hospitalization—Changes in measures of 
discrimination with the addition of variables for the composite of cardiovascular death and 
HF hospitalization are shown in Figure 2c, Figure 3c, and Supplemental Table 4. In the 
overall cohort, baseline clinical information alone yielded a C-index of 0.68, increasing to 
0.74 for the full model. The NRI improved from 0.009 with inclusion of the KCCQ score to 
0.12 for the full model. In the subset of patients with NT-proBNP levels available, inclusion 
of clinical, KCCQ, and laboratory information yielded a C-index of 0.75, increasing to a 
maximum of 0.76 with the inclusion of additional information. The NRI increased from 
0.138 for the model with clinical, KCCQ, and laboratory information, to 0.172 for the full 
model. When variables were examined on an individual basis, NT-proBNP was the strongest 
individual predictor for all clinical outcomes when it was included in the modeling, with the 
highest χ2 for all clinical outcomes (Supplemental Table 5). In the absence of NT-proBNP 
values, exercise, patient symptoms, and echocardiographic variables showed strong 
individual prognostic value (Supplemental Table 5).
Sensitivity Analysis—We performed a sensitivity analysis, by considering the 6MWD 
prior to laboratory information, as this assessment is theoretically cheaper and easier to 
perform in the outpatient setting (Supplemental Tables 6–8). For the composite of all-cause 
mortality and hospitalization, the NRI improved from 0.017 for baseline clinical 
information, KCCQ, and 6MWD, to 0.065 with laboratory data, and 0.109 for the overall set 
of variables. When this analysis was performed in the patients with available NT-proBNP 
levels, the increase in NRI was more dramatic (0.016→0.130), with modest increases for the 
full model (0.162). The C-index increased from 0.64 for the baseline clinical model+KCCQ
+6MWD to 0.67 with laboratory information (including NT-proBNP), and did not increase 
further with inclusion of other variables. For the outcome of all-cause mortality, the increase 
in NRI was similarly higher in the cohort with available NTproBNP levels (clinical 
information+KCCQ+6MWD=0.014; +laboratories=0.085; full=0.094) than in those without 
(clinical information+KCCQ+6MWD=0.007; +laboratories=0.056; full=0.079). For the 
outcome of cardiovascular death and HF hospitalization, similar trends were noted, with 
large increases in C-statistics and NRI after inclusion of laboratory data with NT-proBNP.
Incremental Cost of Assessments—Figure 4 depicts the additional costs of each set of 
assessments, based on Medicare and Medicaid reimbursement data, with the clinical 
assessment and quality of life survey as the referent. All assessments together were close to 
$500; the largest increases in cost were related to echocardiography and exercise testing. 
The addition of NT-proBNP increased the cost of each assessment by approximately $50. Of 
note, costs would be expected to vary considerably based on geographic region and 
insurance status, and true costs may be higher in clinical practice.
Discussion
We examined the incremental prognostic value of sequential clinical assessments in a large 
cohort of ambulatory chronic systolic HF patients. We found that the addition of testing 
beyond clinical and laboratory assessments, such as echocardiography and cardiopulmonary 
exercise testing, yielded diminishing gains in the C-index and measures of appropriate risk 
reclassification—especially with the addition of NT-proBNP levels. In the absence of 
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contemporary guideline-based therapeutic recommendations for chronic HF relying on a 
detailed qualification of individual patient risk, the clinical benefit of increasingly complex 
testing, when done for purposes of prognostication, should be carefully weighed against 
potential discomfort to the patient and escalation in overall cost of care.
Our findings have several important clinical implications. First, to our knowledge, our study 
is the first to consider the prognostic value of evaluations in chronic HF patients with regard 
to how these evaluations are typically performed in the outpatient setting, beginning with a 
comprehensive clinical evaluation, followed by laboratory, echocardiography, and 
cardiopulmonary exercise testing. Prior multivariable risk prediction models have treated 
variables based on their individual prognostic merit without consideration to each variables’ 
place in the assessment timeline (i.e., whether or not a variable might belong to a “bundle” 
of assessments like sodium, blood urea nitrogen, and creatinine). Prior risk prediction 
models, such as those derived from the Candesartan in Heart Failure-Assessment of 
Reduction in Mortality and Morbidity (CHARM) and Controlled Rosuvastatin Multinational 
Study in Heart Failure (CORONA) trials, include variables that are not commonly assessed 
in chronic HF patients, but yield similar values to ours for C-statistics predicting all-cause 
mortality (Supplemental Table 9). Furthermore, a recent pooled analysis of 39,372 patients 
from several cohort studies derived a prediction model that included mostly clinical 
variables and required assessment of LVEF, but did not include natriuretic peptide levels, 
which are an AHA/American College of Cardiology (ACC) Class 1 recommendation for the 
prognostic evaluation of chronic HF.4 This is a key point as, in our analysis, much of the 
improvement in prognostic ability was from inclusion of the natriuretic peptide levels.
Second, we believe our findings draw attention to the possibility that increasing the cost and 
complexity of HF evaluations may only provide modest gains in prognostic predictive 
ability. None of the AHA/ACC guidelines for the management of stable chronic systolic HF 
require a precise assessment of patient prognosis; rather, treatment recommendations are 
based on broad classifications such as NYHA class, LVEF cut-points, and HF stage.1 
Nonetheless, improving prognostic evaluations of chronic HF patients are the subject of 
intense research activity, with novel imaging methodologies, biomarkers, and multivariable 
risk scores being introduced on a regular basis. The uptake of these new assessments relies 
on the assumption that risk stratification may help guide therapeutic decision-making by 
identifying those patients needing more intensive monitoring and therapy.1,4,12 Yet to our 
knowledge, it remains unclear if patients with a higher estimated risk would benefit from 
more intensive treatment, particularly since in certain cases (such as implantable 
cardioverter defibrillator use), more aggressive treatment of sicker patients may lead to more 
harm than benefit.13
Third, beyond the unclear capacity for aiding therapeutic decision-making, our findings 
highlight the notion that diagnostic testing in HF, for the purposes of improved 
prognostication, carries potential economic implications. Recognizing the importance of 
economic considerations, the AHA and ACC have indicated that they will begin to use cost 
data in their clinical practice guidelines and performance standards to rate the value of 
treatments.14 To illustrate the significance of economic factors in the field of cardiology, we 
can consider the rapid growth in reimbursements for cardiac imaging from the Centers for 
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Medicare & Medicaid Services over the last decade, primarily from large increases in 
utilization.15 However, despite the exceptional monetary cost, it remains unclear as to the 
extent to which additional information provided by further testing in HF adds value to 
therapeutic decision-making. Furthermore, with the rapid growth of HF prevalence 
internationally, populations with fewer resources will need to identify more cost-effective 
methods of managing chronic HF, rather than recapitulating or building on current practices. 
Our study suggests that a comprehensive history, physical exam, assessment of quality of 
life, and laboratory testing— especially one that that includes natriuretic peptide levels— 
may provide similar prognostic value to that of a full assessment including assessments of 
left ventricular function and exercise testing.
Limitations
Our study has several limitations that need careful consideration. First, our findings only 
pertain to the incremental prognostic value of clinical testing— there are numerous other 
reasons why testing may be performed on patients with HF to guide therapeutic decision 
making (e.g., timing of surgery). Second, exercise testing in HF-ACTION was not 
performed for ischemia evaluation, which is the most frequent reason why it is performed in 
the clinical setting. Third, patients qualifying for the HF-ACTION study required an LVEF 
of <35% at the outset; therefore, the patient population was already known to have systolic 
HF prior to the study echocardiogram. Fourth, all testing were done for research purposes 
rather than for clinical care. While this is a limitation of the majority of clinical trials, we 
cannot draw firm conclusions about how this information might have different clinical 
implications outside of a study setting where there is often incomplete data available. Our 
study population also consisted of only ambulatory patients with impaired ejection fraction 
(LVEF <35%), so our results may not be generalizable to the general population of HF 
patients. Fifth, since we only considered prognosis with regard to pre-specified outcomes 
used in the original study, observed associations may vary when considering additional 
clinical endpoints. Sixth, there was far greater improvement in net reclassification indices 
among patients without events than in those with events, indicating that additional data may 
improve discrimination more in this group of patients. Lastly, these findings should be 
considered hypothesis generating, and require replication and validation in additional 
cohorts of chronic HF patients.
Conclusions
In conclusion, we examined the incremental prognostic value of sequential clinical 
assessments in a large cohort of well-treated chronic systolic HF patients. Clinical data and 
readily available laboratory tests may provide similar prognostic information to more 
complex models that include assessments of echocardiographic and exercise variables. In 
the absence of clear linkage between precise estimation of risk and specific therapies, the 
marginal benefit of increasingly complex prognostic evaluations should be weighed against 
potential risk to the patient and escalation in costs of care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Analysis Flow
Study flow showing characteristics of the patient population and components of the 
sequential assessments.
BMI indicates body mass index; CCS, Canadian Cardiovascular Society; COPD, chronic 
obstructive pulmonary disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HF, 
heart failure; HF-ACTION, Details of the Heart Failure: A Controlled Trial Investigating 
Outcomes of Exercise Training; HR, heart rate; LVEF, left ventricular ejection fraction; NT-
proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; 
PVD, peripheral vascular disease; SBP, systolic blood pressure; VO2, oxygen consumption; 
6MWD, 6-minute walk distance
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Figure displays improvements in C-statistic with incremental addition of variables for all 
clinical outcomes: a) all-cause death/hospitalization; b) all-cause death; and c) CV death/HF 
hospitalization.
CV indicates cardiovascular; HF, heart failure; NT-proBNP, N-terminal pro-B-type 
natriuretic peptide; C: Clinical Assessment; K: Kansas City Cardiomyopathy Questionnaire; 
L: Laboratory Assessments; E: Echocardiographic Parameters, S: Six Minute Walk 
Distance, F: Full.
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Reclassification of prediction of: a) all-cause mortality/hospitalization; b) all-cause 
mortality; and c) CV death/HF hospitalization with incremental addition of variables.
CV indicates cardiovascular; HF, heart failure; KCCQ, Kansas City Cardiomyopathy 
Questionnaire; NRI, Net Reclassification Index; NT-proBNP, N-terminal pro-B-type 
natriuretic peptide.
Triangles represent NRI for non-events, circles represent NRI for events, and squares 
represent overall NRI.
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Figure 4. Additional Costs
This figure displays the additional costs of incremental testing.
KCCQ indicates Kansas City Cardiomyopathy Questionnaire; NT-proBNP, N-terminal pro-
B-type natriuretic peptide
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